- Home
- REE vs IFRX Comparison
REE vs IFRX Comparison
Compare REE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- IFRX
- Stock Information
- Founded
- REE 2011
- IFRX 2007
- Country
- REE Israel
- IFRX Germany
- Employees
- REE N/A
- IFRX N/A
- Industry
- REE Auto Manufacturing
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- IFRX Health Care
- Exchange
- REE Nasdaq
- IFRX Nasdaq
- Market Cap
- REE 77.3M
- IFRX 65.8M
- IPO Year
- REE N/A
- IFRX 2017
- Fundamental
- Price
- REE $0.61
- IFRX $0.79
- Analyst Decision
- REE Strong Buy
- IFRX Strong Buy
- Analyst Count
- REE 2
- IFRX 4
- Target Price
- REE $11.75
- IFRX $7.75
- AVG Volume (30 Days)
- REE 238.9K
- IFRX 875.8K
- Earning Date
- REE 07-01-2025
- IFRX 08-07-2025
- Dividend Yield
- REE N/A
- IFRX N/A
- EPS Growth
- REE N/A
- IFRX N/A
- EPS
- REE N/A
- IFRX N/A
- Revenue
- REE $183,000.00
- IFRX $140,242.00
- Revenue This Year
- REE $7,039.34
- IFRX N/A
- Revenue Next Year
- REE $2,159.93
- IFRX $6,309.47
- P/E Ratio
- REE N/A
- IFRX N/A
- Revenue Growth
- REE N/A
- IFRX 30.90
- 52 Week Low
- REE $0.61
- IFRX $0.71
- 52 Week High
- REE $11.72
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- REE 24.83
- IFRX 34.33
- Support Level
- REE $0.62
- IFRX $0.75
- Resistance Level
- REE $0.67
- IFRX $0.83
- Average True Range (ATR)
- REE 0.05
- IFRX 0.05
- MACD
- REE 0.07
- IFRX -0.00
- Stochastic Oscillator
- REE 3.10
- IFRX 29.85
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.